A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects

Trial Profile

A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Anthrax; Bacteraemia; Clostridium infections; Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors The Medicines Company
  • Most Recent Events

    • 25 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 15 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top